Rare disease
Showing all 2 results
-
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2021 to 2030. In 2021, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2017 to 2030.
-
Progressive Supranuclear Palsy (PSP) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsProgressive supranuclear palsy (PSP) treatment landscape reflects a huge unmet need, as it is quite dry and limited to symptomatic and supportive care, with no disease-modifying therapies. Emerging therapies like RT-001 (Retrotope), Fasudil (Woolsey), Ezeprogind (AlzProtect), Emeramide (EmeraMed) and Droxidopa (H. Lundbeck) has the potential to overcome the challenges associated with the current therapeutic options in future. Sales of these emerging therapies to treat Progressive Supranuclear Palsy (PSP) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.3 billion market by 2030.